Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Lexicon Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Lexicon Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $60.27M, down 27.8% year over year. For fiscal 2025 it was $61.12M, down 27.7% from the year before. Over ten years it grew -4.3% a year on average. The highest annual figure on record is $163.97M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.12M | -27.7% |
| FY2024 | Dec 31, 2024 | $84.48M | +43.5% |
| FY2023 | Dec 31, 2023 | $58.89M | +11.5% |
| FY2022 | Dec 31, 2022 | $52.82M | -4.1% |
| FY2021 | Dec 31, 2021 | $55.05M | -64.2% |
| FY2020 | Dec 31, 2020 | $153.62M | +67.1% |
| FY2019 | Dec 31, 2019 | $91.92M | -8.3% |
| FY2018 | Dec 31, 2018 | $100.24M | -34.1% |
| FY2017 | Dec 31, 2017 | $152.22M | -7.2% |
| FY2016 | Dec 31, 2016 | $163.97M | +72.3% |
| FY2015 | Dec 31, 2015 | $95.19M | +6.6% |
| FY2014 | Dec 31, 2014 | $89.28M | -0.4% |
| FY2013 | Dec 31, 2013 | $89.68M | +8.6% |
| FY2012 | Dec 31, 2012 | $82.57M | -10.1% |
| FY2011 | Dec 31, 2011 | $91.83M | +16.9% |
| FY2010 | Dec 31, 2010 | $78.52M | -3.3% |
| FY2009 | Dec 31, 2009 | $81.24M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.44M | +10.8% |
| Q1 FY2026 | Mar 31, 2026 | $12.76M | -16.6% |
| Q4 FY2025 | Dec 31, 2025 | $11.32M | -57.6% |
| Q3 FY2025 | Sep 30, 2025 | $18.76M | -27.2% |
| Q2 FY2025 | Jun 30, 2025 | $15.75M | -10.7% |
| Q1 FY2025 | Mar 31, 2025 | $15.30M | +6.5% |
| Q4 FY2024 | Dec 31, 2024 | $26.69M | +80.8% |
| Q3 FY2024 | Sep 30, 2024 | $25.78M | +46.8% |
| Q2 FY2024 | Jun 30, 2024 | $17.64M | +21.3% |
| Q1 FY2024 | Mar 31, 2024 | $14.37M | +19.5% |
| Q4 FY2023 | Dec 31, 2023 | $14.76M | +5.6% |
| Q3 FY2023 | Sep 30, 2023 | $17.56M | +66.3% |
| Q2 FY2023 | Jun 30, 2023 | $14.54M | +8.9% |
| Q1 FY2023 | Mar 31, 2023 | $12.03M | -19.4% |
| Q4 FY2022 | Dec 31, 2022 | $13.98M | -15.3% |
| Q3 FY2022 | Sep 30, 2022 | $10.56M | -32.7% |
| Q2 FY2022 | Jun 30, 2022 | $13.36M | +30.2% |
| Q1 FY2022 | Mar 31, 2022 | $14.93M | +18.4% |
| Q4 FY2021 | Dec 31, 2021 | $16.50M | +1563.1% |
| Q3 FY2021 | Sep 30, 2021 | $15.68M | -60.9% |
| Q2 FY2021 | Jun 30, 2021 | $10.26M | -82.1% |
| Q1 FY2021 | Mar 31, 2021 | $12.61M | -77.1% |
| Q4 FY2020 | Dec 31, 2020 | $992.00K | -97.6% |
| Q3 FY2020 | Sep 30, 2020 | $40.15M | +50.6% |
| Q2 FY2020 | Jun 30, 2020 | $57.30M | +353.4% |
| Q1 FY2020 | Mar 31, 2020 | $55.18M | +359.0% |
| Q4 FY2019 | Dec 31, 2019 | $40.61M | +229.9% |
| Q3 FY2019 | Sep 30, 2019 | $26.66M | +93.7% |
| Q2 FY2019 | Jun 30, 2019 | $12.64M | -52.3% |
| Q1 FY2019 | Mar 31, 2019 | $12.02M | -74.8% |
| Q4 FY2018 | Dec 31, 2018 | $12.31M | -71.1% |
| Q3 FY2018 | Sep 30, 2018 | $13.76M | -64.8% |
| Q2 FY2018 | Jun 30, 2018 | $26.48M | -1.7% |
| Q1 FY2018 | Mar 31, 2018 | $47.70M | +9.4% |
| Q4 FY2017 | Dec 31, 2017 | $42.57M | +62.3% |
| Q3 FY2017 | Sep 30, 2017 | $39.14M | -25.5% |
| Q2 FY2017 | Jun 30, 2017 | $26.93M | – |
| Q1 FY2017 | Mar 31, 2017 | $43.58M | – |
| Q4 FY2016 | Dec 31, 2016 | $26.22M | – |
| Q3 FY2016 | Sep 30, 2016 | $52.53M | – |
See a number that looks wrong?